
Synthetic Peptide Analogues
PT-141
10mgC₅₀H₆₈N₁₄O₁₀
Key Research Findings
- Characterisation of the cyclic heptapeptide with C-terminal carboxyl terminus.
- Published MC3R / MC4R receptor-binding assay data.
- In-vitro CNS receptor-distribution studies.
Overview
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin-receptor agonist with a free C-terminal carboxyl group. Supplied as a lyophilised powder for in-vitro research use only.
Mechanism of Action
Reported in published in-vitro studies as a melanocortin-receptor ligand active at MC3R and MC4R receptor-binding assays. Not intended for human or veterinary use.
Research Effects
MC3R / MC4R Receptor Binding
Extensive ResearchCharacterised in receptor-binding assays as a ligand of MC3R and MC4R melanocortin-receptor subtypes.
Receptor-Distribution Studies
Moderate ResearchPublished in-vitro studies report receptor-distribution profiles in cell-line and tissue assays.
MC1R Cross-Reactivity
Moderate ResearchReceptor-selectivity studies report secondary MC1R binding under assay conditions tested.
Laboratory Research Only — All information on this page is provided for scientific research purposes only. This is a certified reference material sample sold and distributed for laboratory research only.
Quick Facts
Research Status Key

